Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Sep;81(2):336–341. doi: 10.1038/sj.bjc.6690697

Dose-related nephrotoxicity of carboplatin in children

M W English 1, R Skinner 1, A D J Pearson 1, L Price 1, R Wyllie 1, A W Craft 1
PMCID: PMC2362870  PMID: 10496362

Abstract

This study investigated changes and the time course of these changes in renal function in children following treatment with carboplatin, and identified risk factors for nephrotoxicity. Glomerular and proximal renal tubular function were investigated before and up to 2 years after treatment in 23 children who received carboplatin. The main findings were reduced glomerular filtration rate (GFR), and increased renal tubular loss of magnesium, manifested by a low serum magnesium (S Mg). The mean fall in GFR was 22 ml min−1 1.73 m−2 (P = 0.012), and in S Mg it was 0.17 mmol l−1 (P = 0.0077). No patient had a clinically important reduction in GFR, and only one patient had symptomatic hypomagnesaemia. GFR and S Mg did not change over time after completion of treatment. Cumulative dose (CD) of carboplatin was inversely related to mean S Mg at the end of treatment (P = 0.031), and directly related to the fall in S Mg (P < 0.001). Calculated cumulative area under the plasma concentration versus time curve (AUC) of carboplatin was inversely related to S Mg after treatment (P = 0.004). Dose intensity (DI) of carboplatin was not shown to be related to S Mg following treatment. CD, AUC and DI of carboplatin were not related to GFR, nor change in GFR, after treatment. High CDs of carboplatin may be associated with evidence of renal damage qualitatively similar to but less severe than that caused by cisplatin. GFR and SMg should be carefully monitored when high CDs of carboplatin are used, or if carboplatin is combined with other nephrotoxic chemotherapy. © 1999 Cancer Research Campaign

Keywords: carboplatin, children, renal function, nephrotoxicity, adverse effects, chemotherapy

Full Text

The Full Text of this article is available as a PDF (82.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bitran J. D., Desser R. K., Billings A. A., Kozloff M. F., Shapiro C. M. Acute nephrotoxicity following cis-dichlorodiammine-platinum. Cancer. 1982 May 1;49(9):1784–1788. doi: 10.1002/1097-0142(19820501)49:9<1784::aid-cncr2820490909>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  2. Brandt L. J., Broadbent V. Nephrotoxicity following carboplatin use in children: is routine monitoring of renal function necessary? Med Pediatr Oncol. 1993;21(1):31–35. doi: 10.1002/mpo.2950210107. [DOI] [PubMed] [Google Scholar]
  3. Brock P. R., Koliouskas D. E., Barratt T. M., Yeomans E., Pritchard J. Partial reversibility of cisplatin nephrotoxicity in children. J Pediatr. 1991 Apr;118(4 Pt 1):531–534. doi: 10.1016/s0022-3476(05)83372-4. [DOI] [PubMed] [Google Scholar]
  4. Broun E. R., Nichols C. R., Einhorn L. H., Tricot G. J. Salvage therapy with high-dose chemotherapy and autologous bone marrow support in the treatment of primary nonseminomatous mediastinal germ cell tumors. Cancer. 1991 Oct 1;68(7):1513–1515. doi: 10.1002/1097-0142(19911001)68:7<1513::aid-cncr2820680708>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  5. Buckley J. E., Clark V. L., Meyer T. J., Pearlman N. W. Hypomagnesemia after cisplatin combination chemotherapy. Arch Intern Med. 1984 Dec;144(12):2347–2348. [PubMed] [Google Scholar]
  6. Castel V., Badal M. D., Bezanilla J. L., Llombart A., Ruiz-Jiménez J. I., Sánchez de Toledo J., Melero C., Mulet J. Treatment of stage III neuroblastoma with emphasis on intensive induction chemotherapy: a report from the Neuroblastoma Group of the Spanish Society of Pediatric Oncology. Med Pediatr Oncol. 1995 Jan;24(1):29–35. doi: 10.1002/mpo.2950240107. [DOI] [PubMed] [Google Scholar]
  7. Castello M. A., Clerico A., Jenkner A., Dominici C. A pilot study of high-dose carboplatin and pulsed etoposide in the treatment of childhood solid tumors. Pediatr Hematol Oncol. 1990;7(2):129–135. doi: 10.3109/08880019009033382. [DOI] [PubMed] [Google Scholar]
  8. Corbett R., Pinkerton R., Pritchard J., Meller S., Lewis I., Kingston J., McElwain T. Pilot study of high-dose vincristine, etoposide, carboplatin and melphalan with autologous bone marrow rescue in advanced neuroblastoma. Eur J Cancer. 1992;28A(8-9):1324–1328. doi: 10.1016/0959-8049(92)90509-z. [DOI] [PubMed] [Google Scholar]
  9. Doz F., Pinkerton R. What is the place of carboplatin in paediatric oncology? Eur J Cancer. 1994;30A(2):194–201. doi: 10.1016/0959-8049(94)90086-8. [DOI] [PubMed] [Google Scholar]
  10. Elias A. D., Ayash L. J., Eder J. P., Wheeler C., Deary J., Weissman L., Schryber S., Hunt M., Critchlow J., Schnipper L. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. J Clin Oncol. 1991 Feb;9(2):320–327. doi: 10.1200/JCO.1991.9.2.320. [DOI] [PubMed] [Google Scholar]
  11. Ettinger L. J., Gaynon P. S., Krailo M. D., Ru N., Baum E. S., Siegel S. E., Hammond G. D. A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Childrens Cancer Group. Cancer. 1994 Feb 15;73(4):1297–1301. doi: 10.1002/1097-0142(19940215)73:4<1297::aid-cncr2820730427>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  12. Flombaum C. D. Hypomagnesemia associated with cisplatin combination chemotherapy. Arch Intern Med. 1984 Dec;144(12):2336–2337. [PubMed] [Google Scholar]
  13. Frappaz D., Michon J., Hartmann O., Bouffet E., Lejars O., Rubie H., Gentet J. C., Chastagner P., Sariban E., Brugiere L. Etoposide and carboplatin in neuroblastoma: a French Society of Pediatric Oncology phase II study. J Clin Oncol. 1992 Oct;10(10):1592–1601. doi: 10.1200/JCO.1992.10.10.1592. [DOI] [PubMed] [Google Scholar]
  14. Frenkel J., Kool G., de Kraker J. Acute renal failure in high dose carboplatin chemotherapy. Med Pediatr Oncol. 1995 Dec;25(6):473–474. doi: 10.1002/mpo.2950250610. [DOI] [PubMed] [Google Scholar]
  15. Gordon S. J., Pearson A. D., Reid M. M., Craft A. W. Toxicity of single-day high-dose vincristine, melphalan, etoposide and carboplatin consolidation with autologous bone marrow rescue in advanced neuroblastoma. Eur J Cancer. 1992;28A(8-9):1319–1323. doi: 10.1016/0959-8049(92)90508-y. [DOI] [PubMed] [Google Scholar]
  16. Goren M. P., Forastiere A. A., Wright R. K., Horowitz M. E., Dodge R. K., Kamen B. A., Viar M. J., Pratt C. B. Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity. Cancer Chemother Pharmacol. 1987;19(1):57–60. doi: 10.1007/BF00296257. [DOI] [PubMed] [Google Scholar]
  17. Hardy J. R., Tan S., Fryatt I., Wiltshaw E. How nephrotoxic is carboplatin? Br J Cancer. 1990 Apr;61(4):644–644. doi: 10.1038/bjc.1990.143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hill J. B., Russo A. Cisplatin-induced hypomagnesemic hypocalcemia. Arch Intern Med. 1981 Jul;141(8):1100–1100. [PubMed] [Google Scholar]
  19. Lashford L. S., Campbell R. H., Gattamaneni H. R., Robinson K., Walker D., Bailey C. An intensive multiagent chemotherapy regimen for brain tumours occurring in very young children. Arch Dis Child. 1996 Mar;74(3):219–223. doi: 10.1136/adc.74.3.219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Marina N. M., Rodman J., Shema S. J., Bowman L. C., Douglass E., Furman W., Santana V. M., Hudson M., Wilimas J., Meyer W. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. J Clin Oncol. 1993 Mar;11(3):554–560. doi: 10.1200/JCO.1993.11.3.554. [DOI] [PubMed] [Google Scholar]
  21. Mason M. D., Nicholls J., Horwich A. The effect of carboplatin on renal function in patients with metastatic germ cell tumours. Br J Cancer. 1991 Apr;63(4):630–633. doi: 10.1038/bjc.1991.144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. McDonald B. R., Kirmani S., Vasquez M., Mehta R. L. Acute renal failure associated with the use of intraperitoneal carboplatin: a report of two cases and review of the literature. Am J Med. 1991 Mar;90(3):386–391. [PubMed] [Google Scholar]
  23. Newell D. R., Pearson A. D., Balmanno K., Price L., Wyllie R. A., Keir M., Calvert A. H., Lewis I. J., Pinkerton C. R., Stevens M. C. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group. J Clin Oncol. 1993 Dec;11(12):2314–2323. doi: 10.1200/JCO.1993.11.12.2314. [DOI] [PubMed] [Google Scholar]
  24. Nichols C. R., Andersen J., Lazarus H. M., Fisher H., Greer J., Stadtmauer E. A., Loehrer P. J., Trump D. L. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol. J Clin Oncol. 1992 Apr;10(4):558–563. doi: 10.1200/JCO.1992.10.4.558. [DOI] [PubMed] [Google Scholar]
  25. Pinkerton C. R., Broadbent V., Horwich A., Levitt J., McElwain T. J., Meller S. T., Mott M., Oakhill A., Pritchard J. 'JEB'--a carboplatin based regimen for malignant germ cell tumours in children. Br J Cancer. 1990 Aug;62(2):257–262. doi: 10.1038/bjc.1990.272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Salem P., Khalyl M., Jabboury K., Hashimi L. Cis-diamminedichloroplatinum (II) by 5-day continuous infusion. A new dose schedule with minimal toxicity. Cancer. 1984 Feb 15;53(4):837–840. doi: 10.1002/1097-0142(19840215)53:4<837::aid-cncr2820530403>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  27. Shea T. C., Flaherty M., Elias A., Eder J. P., Antman K., Begg C., Schnipper L., Frei E., 3rd, Henner W. D. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol. 1989 May;7(5):651–661. doi: 10.1200/JCO.1989.7.5.651. [DOI] [PubMed] [Google Scholar]
  28. Shea T. C., Storniolo A. M., Mason J. R., Newton B., Mullen M., Taetle R., Green M. R. A dose-escalation study of carboplatin/cyclophosphamide/etoposide along with autologous bone marrow or peripheral blood stem cell rescue. Semin Oncol. 1992 Feb;19(1 Suppl 2):139–144. [PubMed] [Google Scholar]
  29. Siegert W., Beyer J., Strohscheer I., Baurmann H., Oettle H., Zingsem J., Zimmermann R., Bokemeyer C., Schmoll H. J., Huhn D. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. J Clin Oncol. 1994 Jun;12(6):1223–1231. doi: 10.1200/JCO.1994.12.6.1223. [DOI] [PubMed] [Google Scholar]
  30. Skillen A. W., Buamah P. K., Cantwell B. M., Cornell C., Hodson A. W., Harris A. L. Urinary protein and enzyme excretion in patients receiving chemotherapy with the cis-platinum analogs carboplatin (CBDCA, JM8) and iproplatin (CHIP, JM9). Cancer Chemother Pharmacol. 1988;22(3):228–234. doi: 10.1007/BF00273416. [DOI] [PubMed] [Google Scholar]
  31. Skinner R., Pearson A. D., Coulthard M. G., Skillen A. W., Hodson A. W., Goldfinch M. E., Gibb I., Craft A. W. Assessment of chemotherapy-associated nephrotoxicity in children with cancer. Cancer Chemother Pharmacol. 1991;28(2):81–92. doi: 10.1007/BF00689694. [DOI] [PubMed] [Google Scholar]
  32. Sleijfer D. T., Smit E. F., Meijer S., Mulder N. H., Postmus P. E. Acute and cumulative effects of carboplatin on renal function. Br J Cancer. 1989 Jul;60(1):116–120. doi: 10.1038/bjc.1989.233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Stevens M. C., Lewis I. J., Pearson A. J., Pinkerton C. R. Carboplatin and renal function in children. Br J Cancer. 1991 Jan;63(1):158–158. doi: 10.1038/bjc.1991.34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Tscherning C., Rubie H., Chancholle A., Claeyssens S., Robert A., Fabre J., Bouissou F. Recurrent renal salt wasting in a child treated with carboplatin and etoposide. Cancer. 1994 Mar 15;73(6):1761–1763. doi: 10.1002/1097-0142(19940315)73:6<1761::aid-cncr2820730635>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  35. Wilson W. H., Jain V., Bryant G., Cowan K. H., Carter C., Cottler-Fox M., Goldspiel B., Steinberg S. M., Longo D. L., Wittes R. E. Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. J Clin Oncol. 1992 Nov;10(11):1712–1722. doi: 10.1200/JCO.1992.10.11.1712. [DOI] [PubMed] [Google Scholar]
  36. Womer R. B., Pritchard J., Barratt T. M. Renal toxicity of cisplatin in children. J Pediatr. 1985 Apr;106(4):659–663. doi: 10.1016/s0022-3476(85)80098-6. [DOI] [PubMed] [Google Scholar]
  37. de Camargo B., Melaragno R., Saba e Silva N., Mendonça N., Alvares M. N., Morinaka E., Marques A., Cusato M. P. Phase II study of carboplatin as a single drug for relapsed Wilms' tumor: experience of the Brazilian Wilms' Tumor Study Group. Med Pediatr Oncol. 1994;22(4):258–260. doi: 10.1002/mpo.2950220409. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES